Stay updated on MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page.

Latest updates to the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe study locations were expanded to include many new sites across the US, Canada, and other regions, and the HHS Vulnerability Disclosure link was removed.SummaryDifference2%

- Check23 days agoNo Change Detected
- Check44 days agoChange DetectedA new sentence is added to Publications indicating publications are provided voluntarily by the submitter, and the descriptor changes from 'about the study results' to 'about the results of the study'; the revision tag updates to v3.3.2 (replacing v3.2.0).SummaryDifference0.3%

- Check52 days agoChange DetectedThe page's notice about government funding status was removed; no study content was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check66 days agoChange DetectedNo significant changes detected on the Study Details page; the study overview, design, eligibility criteria, outcomes, and locations remain unchanged.SummaryDifference0.2%

- Check88 days agoChange DetectedThe page has updated time/status information and removed older status labels; latest dates and counts are now reflected.SummaryDifference0.3%

- Check95 days agoChange DetectedMajor update: added government-operating status notice and links; version bumped from v3.1.0 to v3.2.0 indicating a new release.SummaryDifference1.0%

Stay in the know with updates to MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page.